Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Hodgkiss

Diagnostic Radiology Memphis, TN Medical Doctor

NPI 1568494631 CMS profile 343584

5683 S Rex Rd, Memphis, TN 38119

Open in the dashboard

General payments

$169,535

462 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Hodgkiss of Memphis, TN is reported in the CMS Open Payments database as having received $169,535 across 462 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $100,711 96
2024 General $56,600 82
2023 General $1,848 56
2022 General $2,054 75
2021 General $2,766 57
2020 General $680 35
2019 General $4,876 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Hodgkiss
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Thomas Hodgkiss were reported at $100,711. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Thomas Hodgkiss Diagnostic Radiology median Middle half National median
2019 $4,876 $108 $29–$318 $163
2020 $680 $65 $21–$252 $114
2021 $2,766 $92 $24–$292 $132
2022 $2,054 $104 $29–$294 $149
2023 $1,848 $110 $29–$337 $160
2024 $56,600 $113 $30–$356 $164
2025 $100,711 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $154,983 65 payments
  2. Abbott Laboratories $3,925 88 payments
  3. Boston Scientific Corporation $3,751 141 payments
  4. Medtronic, Inc. $1,661 38 payments
  5. Stryker Corporation $1,420 6 payments
  6. Genesys Orthopedics Systems, L.L.C. $1,042 6 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $322 17 payments
  8. Terumo Medical Corporation $216 6 payments
  9. Gentleman Orthopedic Solutions $199 2 payments
  10. Nevro Corp. $190 8 payments
  11. Other $1,826 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $143,938 6 payments
  2. Food and Beverage $12,935 423 payments
  3. Travel and Lodging $9,168 30 payments
  4. Consulting Fee $3,300 1 payment
  5. Education $179 1 payment
  6. Gift $14 1 payment
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Cv $88,917 3 payments
  2. Auryon Laser System 100-120 Vac Et $55,000 2 payments
  3. AURYON LASER SYSTEM 100-120 VAC Pad $5,649 51 payments
  4. ANGIOVAC $3,702 5 payments
  5. Proclaim Family of SCS IPGs $2,583 45 payments
  6. ALPHAVAC $1,716 4 payments
  7. WaveWriter Alpha Prime 16 $1,390 48 payments
  8. IVS - VERTEBRAL AUGMENTATION PRODUCTS $1,335 5 payments
  9. SACROILIAC JOINT FUSION SYSTEM $1,042 6 payments
  10. Protege Family of SCS IPGs $802 8 payments
  11. Other $6,977 292 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,200

Median for Diagnostic Radiology: 24

Drug cost

$34,379

Median for Diagnostic Radiology: $190

Branded share of claims

56.6%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 14 $13,415
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 297 $7,250
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 163 $3,772
Oxycodone Hcl Generic 102 $2,290
Clopidogrel Clopidogrel Bisulfate Brand 147 $1,925
Morphine Sulfate Er Morphine Sulfate Brand 58 $1,382
Gabapentin Generic 89 $974
Tizanidine Hcl Generic 66 $809
Pregabalin Generic 44 $506
Hydroxychloroquine Sulfate Generic 15 $436

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 129 billing codes

Paid by Medicare

$1,599,324

Of which drugs: $5,571

Medicare patients

646

Average age 72

Services billed

16,170

408 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 47%
Ischemic heart disease 38%
Depression 36%
Chronic kidney disease 35%
COPD 29%
Heart failure 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 98 3,414 $930
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 66 443 $311
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 37 1,926 $173
Injection, hydromorphone, up to 4 mg J1170 Office 25 63 $168
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 74 1,032 $87
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 18 36 $68
Injection, cefazolin sodium, 500 mg J0690 Office 49 110 $65
Injection, ropivacaine hydrochloride, 1 mg J2795 Office 44 1,124 $61
Injection, midazolam hydrochloride, per 1 mg J2250 Office 148 446 $46
Injection, ketorolac tromethamine, per 15 mg J1885 Office 24 60 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $156
$156 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $22
$22 — —
EVENITY
  • Amgen Inc. $15
$15 — —
Prolia
  • Amgen Inc. $15
$15 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

462 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record